Validation of immunogenic PASD1 peptides against HLA-A*24:02 colorectal cancer

Soh, Joanne Ern Chi; Abu, Nadiah; Sagap, Ismail; Mazlan, Luqman; Yahaya, Azyani; Mustangin, Muaatamarulain; Khoo, Tze Sean; Saidin, Sazuita; Ishak, Muhiddin; Mutalib, Nurul Syakima Ab; Jamal, Rahman

doi:10.2217/imt-2019-0073

Cited by 5 publications

(6 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This current study shows the highest PASD1 protein expression in the CRC population (31.7%). A previous study described only 17.4% PASD1 expression in CRC ( Soh et al, 2019 ). The possible reason for these discrepancies was the PASD1 antibodies used in both studies.…”

Section: Discussionmentioning

confidence: 93%

Cancer testis antigen PASD1 expression and immunogenicity in human colorectal cancer and polyps

SUKOR¹,

YAHAYA²,

SAGAP³

et al. 2022

Turkish Journal of Biology

Self Cite

View full text Add to dashboard Cite

Colorectal cancer (CRC) is a malignant tumor arising from a human inner colon lining that may spread to other organs such as the liver and lungs. Per ARNT Sim domain containing 1 (PASD1) is a cancer-testis antigen expressed in cancers including CRC but not in normal tissues except for normal testes. This study aims to study PASD1 protein as a potential target for CRC immunotherapy. A total of 90 CRC and polyps tissue samples were investigated for PASD1 RNA and protein expression using a real-time polymerase chain reaction and immunohistochemical staining, respectively. Matched patients’ peripheral blood mononuclear cells were pulsed with PASD1 peptides and measured for immunogenicity, cell cytotoxicity, and cytokine assays. The clinical data were collected and analyzed accordingly. Our results show that PASD1_v2 mRNA expression was highly expressed in CRC (46.0%) and polyps samples (33.3%). Both PASD1-1 and PASD1-2 proteins were expressed in 31.7% of CRC and 29.4% of polyps samples. Protein expression was weak to moderate positive in the cytoplasm and/or nucleus of the tissues. Immune responses towards CD4-specific PASD1 peptides were detected in 21.7% of CRC and 23.5% of polyps patients. The most immunogenic peptide was PASD1 (1) in CRC while PASD1 (3) in polyps. Cytotoxicity effects were detected up to 57.20% observed in CRC samples while IL-17A and IL-6 cytokines were highly expressed. The demographic data suggest that Chinese female patients more than 60 years old, diagnosed with late-stage rectosigmoid tumors may benefit from the PASD1 peptide immunotherapy approach. This is the first report describing CD4-positive T-helper response to the PASD1 positive CRC patients and its cytotoxicity.

show abstract

Section: Discussionmentioning

confidence: 93%

Cancer testis antigen PASD1 expression and immunogenicity in human colorectal cancer and polyps

SUKOR¹,

YAHAYA²,

SAGAP³

et al. 2022

Turkish Journal of Biology

Self Cite

View full text Add to dashboard Cite

show abstract

“…[ 36 ] PASD1 is an immunogenic protein in colorectal cancer that encourages cell proliferation in glioma cells. [ 37 38 ] In gastric cancer patients, this protein is up-regulated, and this up-regulation has a relationship to OS.…”

Section: Discussionmentioning

confidence: 99%

Identification of Cancer/Testis Antigens Related to Gastric Cancer Prognosis Based on Co-Expression Network and Integrated Transcriptome Analyses

Ansari

Nikpour

2023

Advanced Biomedical Research

View full text Add to dashboard Cite

Background: Gastric cancer is a worldwide life-threatening cancer. The underlying cause of it is still unknown. We have noticed that some cancer/testis antigens (CTAs) are up-regulated in gastric cancer. The role of these genes in gastric cancer development is not fully understood. The main aim of the current study was to comprehensively investigate CTAs' expression and function in stomach adenocarcinoma (STAD). Materials and Methods: A comprehensive list of CTA genes was compiled from different databases. Transcriptome profiles of STAD were downloaded from the cancer genome atlas (TCGA) database and analyzed. Differentially-expressed CTAs were identified. Pathway enrichment analysis, weighted gene correlation network analysis (WGCNA), and overall survival (OS) analysis were performed on differentially-expressed CTA genes. Results: Pathway enrichment analysis indicates that CTA genes are involved in protein binding, ribonucleic acid processing, and reproductive tissues. WGCNA showed that six differentially-expressed CTA genes, namely Melanoma antigen gene (MAGE) family member A3, A6, A12 and chondrosarcoma associated gene (CSAG) 1, 2, and 3, were correlated. Up-regulation of MAGEA11, MAGEC3, Per ARNT SIM domain containing 1 (PASD1), placenta-specific protein 1 (PLAC1) and sperm protein associated with the nucleus X-linked family member (SPANXB1) were significantly associated with lower OS of patients. Conclusion: MAGEA11, MAGEC3, PASD1, PLAC1, and SPANXB1 can be investigated as prognostic biomarkers in basic and clinical studies. Further functional experiments are needed to understand the exact interaction mechanisms of these genes.

show abstract

“…e combination of traditional treatment methods with immune checkpoint inhibitors could provide promising treatment strategies for cancer patients, including CRC [38]. Numerous studies have shown that immunotherapy can inhibit the growth of colorectal cancer cells and prolong the survival period of patients [39][40][41]. In this paper, the correlation between PIGR and immune-associated signatures was explored by comprehensive bioinformatic technologies.…”

Section: Discussionmentioning

confidence: 99%

The Underlying Roles of Exosome-Associated PIGR in Fatty Acid Metabolism and Immune Signaling in Colorectal Cancer

Liu

Deng

2022

Journal of Oncology

View full text Add to dashboard Cite

The polymeric immunoglobulin receptor (PIGR), an exosome-associated glycoprotein, plays an important role in the occurrence and development of different tumors. This study aimed to investigate whether PIGR is essential for colorectal cancer (CRC). Comprehensive bioinformatics analysis and immunohistochemistry (IHC) revealed that expression of PIGR was significantly decreased in CRC patients. Upregulated PIGR displayed favorable prognostic values in CRC patients. Several algorithms, such as TISIDB and TIMER, were used to evaluate the roles of PIGR expression in the regulation of immune response in CRC. Moreover, GSEA enrichment analysis indicated the underlying role of PIGR in the regulation of fatty acid metabolism in CRC. Taken together, our findings might provide a new potential prognostic and immune-associated biomarker for CRC and supply a new destination for PIGR-related immunotherapy in clinical treatment.

show abstract

Validation of immunogenic PASD1 peptides against HLA-A*24:02 colorectal cancer

Cited by 5 publications

References 78 publications

Cancer testis antigen PASD1 expression and immunogenicity in human colorectal cancer and polyps

Cancer testis antigen PASD1 expression and immunogenicity in human colorectal cancer and polyps

Identification of Cancer/Testis Antigens Related to Gastric Cancer Prognosis Based on Co-Expression Network and Integrated Transcriptome Analyses

The Underlying Roles of Exosome-Associated PIGR in Fatty Acid Metabolism and Immune Signaling in Colorectal Cancer

Contact Info

Product

Resources

About